Key Takeaways
- Steady quarter, India soft: Revenue of INR6,957 crores with EBITDA margin of 25.6%, but One India growth of 6% YoY was below management's own expectations due to a weak respiratory season and team restructuring.
- U.S. pipeline is the growth engine: Management reiterated an aspiration for closer to $1 billion in U.S. sales in FY27, driven by gAdvair, gSymbicort, peptide launches, and a new biosimilar, even as Revlimid phases out.
- Biosimilars strategy takes shape: Cipla signed its first U.S. biosimilar deal (filgrastim, launching Q2) and committed over $100 million to a JV for its own assets, targeting a '29-'30 launch window.
- Margins held the line: Gross margin expanded 156 bps YoY to 68.8%, and management maintained its full-year EBITDA margin guidance of 23.5% to 24.5%, absorbing higher R&D and employee costs.
- What to watch next quarter: The U.S. biosimilar launch, the pace of India's branded prescription recovery post-restructuring, and any clarity on the timing of the Revlimid decline.
One India: A Weak Quarter, A Confident Outlook
- Headline growth masked softness: One India breached INR3,000 crores for the first time in a Q1, but the branded prescription business (58-59% of the mix) grew only 4-5%, dragged down by respiratory and anti-infective therapies that saw modest market growth of just 5% each.
- Respiratory hit by a double whammy: An unusual rainy summer suppressed the respiratory season, and price adjustments on some large inhalers from government notifications over the last 12-15 months impacted brand values. Volume growth is coming from categories where Cipla has repositioned, but the net effect was a slowdown.
- Internal disruption added friction: A strategic team realignment to support a new respiratory division for triple-combination launches was completed in April and May, creating temporary execution drag.
- Trade generics and consumer health held up: Trade generics continued strong execution-driven growth, while Nicotex, Omnigel and Cipladine all held number 1 positions in their segments, with consumer health operating profitability improving.
- GLP-1 is the next domestic catalyst: Cipla aims to be among the first wave of semaglutide launches in India; if the market forms early next year, management expects a much faster ramp-up than typical brands given the unmet need, making it a significant FY27 growth driver.
Umang Vohra: "I think the way you make portfolio choices here will be -- will perhaps be the most important."
North America: Pipeline vs. Revlimid Phasing
- Revenue steady at $226 million: Older, larger products are substituting themselves due to price erosion, but new launches like Nano Paclitaxel and Nilotinib are sustaining momentum. Lanreotide has already matched last year's average quarterly sales, with room to grow share.
- The Revlimid overhang: Management called the U.S. trajectory "a little indeterminate" because the timing of Revlimid's decline is uncertain: it could hit in Q2, Q3, or Q4, and prices have already started correcting. Revlimid is expected to be heavier in the first three quarters and peter off in Q4.
- The pipeline answer: Generic Advair is likely an H2 launch this year, generic Symbicort and more inhalation assets are being prepared for later in the fiscal year, and 2-3 peptide assets remain committed for this year. Management believes these will cushion the Revlimid top-line impact and fuel the FY27 $1 billion aspiration.
- Biosimilar entry point: Cipla's first U.S. biosimilar, filgrastim in supportive care oncology, is expected to launch in Q2 FY26 through a partnership. Management did not disclose the partner name, Cipla's specific role, or the deal economics.
- Supply chain de-risking: Roughly one-third of U.S. revenue now comes from each of U.S. facilities, India operations, and strategic partners. The China facility is fully utilized and has begun supplying.
Umang Vohra: "Actually, it's a little indeterminate. And it depends on when Revlimid -- the impact of Revlimid and how it comes off. If we could see a larger impact of Revlimid in quarter 3, we could see it in quarter 4 or in quarter 2, right? So we don't know that, and it's very difficult to give a guidance range."
Biosimilars: Building a Third Engine
- The JV is the long game: Cipla has committed over $100 million to a biosimilar JV, with the remaining 70-80% of that amount to be invested over the next three years. Own biosimilar assets are expected towards the '29-'30 time period.
- Near-term via partnerships: In the interim, Cipla will in-license a few assets through partnerships, starting with the filgrastim launch next quarter. Management deflected on how many more licensed products are coming and on what timeline.
- The investment thesis is improving: Phase III requirements are changing, allowing faster pipeline expansion and lower per-product spend. Management believes the biosimilar engine will begin to mimic the investment return ratio of complex generics, and that increasing competitor entry reduces innovator share, creating more room for generics.
Umang Vohra: "in some way, a biosimilar engine for a company like us will begin to mimic an investment return ratio a little bit more than a complex generics product, but not too far from it."
Margins & Cost Structure
- Gross margin expanded, EBITDA held: Gross margin rose 156 bps YoY to 68.8% on favorable product mix and strategic portfolio management. EBITDA margin of 25.6% keeps the company on track for its full-year guidance of 23.5% to 24.5%.
- R&D and people costs stepped up: Total expenses rose 8% YoY, driven by annual employee increments and increased R&D investment, including API procurement for developmental efforts. Other expenses (ex-R&D) at the Q1 run rate are expected to continue, though Indore remediation costs should come down after reinspection.
- Why not higher margins? When asked if margins should be higher given the rich pipeline (Advair, Abraxane, Nilotinib, Symbicort), management declined, citing product mix, higher R&D, and Revlimid's front-loaded phasing in the first quarters.
- PLI income is material: PLI benefits are a material component of other operating income (INR120 crores), linked to a complex portfolio sold in and outside India, with a government cap per scheme.
Regulatory & Facility Updates
- Two favorable FDA classifications: The Medispray facility at Kundaim, Goa (inspected in Q4 FY24) was classified as VAI during the quarter. The Sitec Labs analytical testing facility in Navi Mumbai, inspected during the quarter, was also classified as VAI.
- Indore reinspection pending: Cipla expects reinspection any time from now until February, which marks the two-year window from the last inspection. The company is prepared and looking forward to it.
- Generic Advair approval pathway: Management welcomed a promulgation signed by the administration for approving U.S. facilities faster, which supports the H2 launch timeline for generic Advair this year.
International Markets (Ex-U.S.)
- One Africa grew 11% YoY in USD: South Africa grew 6% in ZAR terms, with private market secondary growth of 5.6% significantly outperforming the 3.8% market growth. Expansion of the tender business and successful new launches fueled the performance.
- EMEU grew 8% in USD: Growth was driven by impressive performance across both DTM and B2B segments, achieved despite ongoing geopolitical headwinds. Margin stability was maintained by leveraging internal assets.
- GLP-1 opportunities are selective: Cipla will not be in the first wave of GLP-1 launches in Canada, but will be among the first set of launches in some other markets. Management declined to provide specific color on Canada and Brazil launch timing.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | 23.5% to 24.5% range | Full year FY26 |
| U.S. revenue aspiration | Closer to $1 billion | FY27 |
| First U.S. biosimilar launch | Filgrastim (supportive care oncology) | Q2 FY26 |
| Generic Advair U.S. launch | Likely H2 launch | FY26 |
| Peptide launches in U.S. | 2 to 3 assets | FY26 |
| Generic Symbicort launch | Key respiratory launch | Later in FY26 |
| Own biosimilar assets | Via JV investment | '29-'30 time period |
| India business growth | Grow in line with industry | Next 3 quarters |
| Indore facility reinspection | Expected any time | Now to February |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Revenue | ₹6,957 cr, +4% YoY |
| One India revenue | ₹3,000+ cr (breached threshold for first time in an opening quarter), +6% YoY; 44% of global revenue |
| North America revenue | $226 million |
| One Africa revenue growth | +11% YoY in USD terms |
| South Africa revenue growth | +6% YoY in ZAR terms |
| EMEU revenue growth | +8% YoY in USD terms |
| EBITDA margin | 25.6%, broadly flat YoY |
| Gross margin | 68.8%, +156 bps YoY |
| R&D spend | ₹432 cr, 6.2% of revenue |
| Profit after tax | ₹1,298 cr, 18.7% of sales, +10.2% YoY |
| Effective tax rate | 27%, flat YoY |
| Net cash balance | ₹10,379 cr as of June 30; total debt ₹459 cr |
| Full-year EBITDA margin guidance | 23.5% to 24.5% |
| Chronic segment share of branded Rx sales | 61.5% as per IQVIA MAT June '25 |
| Brands in ₹100 cr+ club | 29, 5 added this quarter |
| Albuterol U.S. market share | 19.5%, ranked #1 in Albuterol MDI market |
| One Africa private market secondary growth | 5.6%, vs market growth of 3.8% |